ggabuin Profile Banner
Gonzalo Gomez Abuin Profile
Gonzalo Gomez Abuin

@ggabuin

Followers
220
Following
1K
Media
10
Statuses
324

Oncólogo clínico del Hospital Alemán. Las opiniones son mías

Ciudad Autónoma de Buenos Aire
Joined July 2011
Don't wanna be here? Send us removal request.
@narvaezdanap
Dana Narvaez, MD
2 years
The Argentine group is here at the @myESMO Breast Cancer Preceptorship in Sao Paulo! 🇦🇷 🇧🇷Excited to have @ggabuin as our senior mentor for this occasion! #ESMO #BreastCancer #IAF #CEMIC #Hospitalaleman
3
2
11
@matteolambe
Matteo Lambertini, MD PhD
3 years
Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm https://t.co/lGLX61heDV
7
184
505
@ggabuin
Gonzalo Gomez Abuin
3 years
A great pleasure to have been part of @myESMO Latam Summit. Very nice discussion about BC in Latam with the fantastic colleagues @curijoey, Vicky Constanzo and @fwaisberg1 Thanks to @aaoncoclinica for the excellent organization
@PabloMando
Pablo Mando
3 years
Just ended an outstanding presentation by @ggabuin on Main challenges in the treatment of Breast cancer at ESMO Summit 👏🏻👏🏻👏🏻 a thorough analysis of LATAM situation!!! Highly recommended to look for it in oncology pro @myESMO @curijoey @AndresC27622123
1
6
23
@Martin_AngelMD
Martín Angel
3 years
Great dinner with @aaoncoclinica & @myESMO colleagues. 🇦🇷 🇧🇷 🇵🇪 🇪🇺 #LATAM #ESMOSUMMIT closure @AlbigesL @TeresaSAmaral @curijoey @AndresC27622123 @PabloMando @dlkaen @pekijammer
0
6
17
@ggabuin
Gonzalo Gomez Abuin
3 years
Congratulations to the new elected @myESMO president @FAndreMD and to the directors!
0
0
2
@aaoncoclinica
Asociación Argentina de Oncología Clínica (AAOC)
3 years
Excelente charla del Dr @ggabuin en el #POSTCHICAGO22 sobre cáncer de mama RH+. ASTRAA y ABCSG-18 nos ayudan a confirmar estrategias de mejora en adyuvancia.#AAOC22
2
2
10
@FAndreMD
FabriceAndre
3 years
Don’t forget to vote for @myESMO election of the Executive Board, including the new President Elect. Link below ! Next EB needs a strong support and engagement. Oncology is currently facing major challenges that can be ,at least partially, addressed by @myESMO .
@myESMO
ESMO - Eur. Oncology
3 years
"Cast your votes for the Executive Board candidates that best represent you & will guide our Society to support you as #oncology professionals & fulfil our mission to take the best possible care of our patients" @peters_solange ESMO members 📢 Vote here https://t.co/IwFyaYxMbO
0
11
24
@matteolambe
Matteo Lambertini, MD PhD
3 years
Great to be finally back to the soccer field with the @ASCO vs @myESMO game during #ASCO22: here the pre- and post-match pics 😝💪🔝🤩 @FAndreMD @ggabuin @M_Tagliamento @FiteniFrederic @dr_FPetracci @jo_ciccolini
9
10
99
@matteolambe
Matteo Lambertini, MD PhD
4 years
Updated data from #monarchE trial just presented at #ESMOVirtualPlenary showing increased magnitude of benefit for the addition of #abemaciclib to adjuvant #EndocrineTherapy in high-risk HR+/HER2- #BreastCancer patients: very important data! @myESMO @OncoAlert @Annals_Oncology
3
57
130
@aaoncoclinica
Asociación Argentina de Oncología Clínica (AAOC)
4 years
POST EUROPEO 2021 - Jornada III Módulo 05 - Cáncer de Mama Dr. Gonzalo Gomez Abuin
0
1
7
@aaoncoclinica
Asociación Argentina de Oncología Clínica (AAOC)
4 years
POST EUROPEO 2021: JORNADA III Programa científico disponible en: https://t.co/CeP3dzwftH Inscripción y transmisión en vivo: https://t.co/8BVnPXRRTT Actividad no arancelada - Acceso libre
0
1
3
@ESMO_Open
ESMO Open
4 years
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic #breastcancer patients #ESMO21 @myESMO https://t.co/R7qcaoaonn
1
82
171
@EnriqueSoto8
Enrique Soto
4 years
This @MBakitas #ASCOQLTY21 👇👇👇👇👇👇👇👇👇👇
0
21
67
@PTarantinoMD
Paolo Tarantino
4 years
#ESMO21 delivered once again transformative, practice-changing new data across oncological fields I’m happy to join efforts with @ADesaiMD to select some important #BCSM & #LCSM Take Home messages from the Congress 🇫🇷 Hope to see you all in Paris next year! #ESMO21 @myESMO
2
59
152
@luisgparral
Luis G Parra L
4 years
Invitamos a la comunidad médica y académica, a participar en el Latin American Workshop on Clinical Oncology Research, un espacio que permitirá la colaboración para el desarrollo de la ciencia y las redes médicas en América Latina. Inscripciones aquí 👉🏻 https://t.co/F0RI6OCzqk
2
3
5
@PTarantinoMD
Paolo Tarantino
4 years
TNBC: not so negative anymore! Great recapitulation of the biology and emerging targets in TNBC by @kevinpunie #ESMO21
1
34
110
@drclairebrady
Claire Brady
4 years
#ESMO21 shining industrial spotlights 💥💥 on crucial need for academic led trials to improve cancer outcomes 💥💥 1️⃣ of my fav slides @ggabuin -also highlighting NB of publicly funded research - no KN355/MONALESSA 2 (et al)without it @CancerTrialCork @cancertrials_ie @hseNCCP
@myESMO
ESMO - Eur. Oncology
4 years
#ESMO21: New data from PEACE-1 & STAMPEDE report significant OS improvement in pts (metastatic & non-metastatic) with castration-sensitive #prostatecancer receiving abiraterone upfront 👉 https://t.co/dvwnLQbDUH #pcsm #CSPC #visualabstract @DrChoueiri
0
4
6
@maryam_lustberg
Maryam Lustberg MD, MPH, FASCO
4 years
Significant disparities in #globonc access to drugs. @OncoAlert #ESMO21 @WHO @CancerCareMASCC
0
4
10
@CarmenCriscit
Carmen Criscitiello
4 years
#ESMO21 rocks. Finally OS data from the MONALEESA-2 trial: the longest OS ever reached 👏🏼 🎉 #bcsm @myESMO #livelongerlivebetter
@myESMO
ESMO - Eur. Oncology
4 years
#ESMO21: CDK4/6 inhibitors have led to a paradigm shift in the treatment of HR-positive/HER2-negative #aBC, offering patients the opportunity to live significantly longer and better lives. Editorial by @CarmenCriscit 👉 https://t.co/D48wjeHah8 #bcsm #advancedbreastcancer
4
14
80
@matteolambe
Matteo Lambertini, MD PhD
4 years
Super @BarbaraPistill2 from @GustaveRoussy commenting at #ESMO21 on the #TULIP trial and how to interpret these results after the #DESTINYbreast3 trial with the other #ADC #TrastuzumabDeruxtecan in #HER2+ #BreastCancer patients @OncoAlert @myESMO #ItalianPride #bcsm
0
5
33